United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - alfuzosin hydrochloride - oral suspension - 2mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - dutasteride, quantity: 500 microgram - capsule, soft - excipient ingredients: titanium dioxide; mono- and di- glycerides; lecithin; iron oxide yellow; butylated hydroxytoluene; medium chain triglycerides; gelatin; glycerol - avodart is indicated for use as monotherapy for the management of symptomatic benign prostatic hyperplasia (bph) or as combination therapy with an alpha blocker which is approved for use in bph and which has been dose titrated in accordance with the relevant recommendations in the product information for that alpha blocker.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alfuzosin hydrochloride, quantity: 10 mg - tablet, modified release - excipient ingredients: magnesium stearate; ethylcellulose; microcrystalline cellulose; iron oxide yellow; silicon dioxide; mannitol; hypromellose; hydrogenated castor oil; povidone - indicated for the treatment of the functional symptoms of benign prostatic hyperplasia.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride extended-release tablets, usp are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. alfuzosin hydrochloride extended-release tablets, usp are not indicated for the treatment of hypertension. alfuzosin hydrochloride extended-release tablets, usp are not indicated for use in pediatric population. alfuzosin hydrochloride extended-release tablets are contraindicated for use: - in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [see use in specific populations(8.7)  and clinical pharmacology (12.3)]. - with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [see drug interactions (7.1) and clinical pharmacology (12.3)] . - in patients with known hypersensitivity, such as urticaria and angioedema, to alfuzosin hydrochloride or any component of alfuzo

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride extended-release tablets are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. alfuzosin hydrochloride extended-release tabletsare not indicated for the treatment of hypertension. alfuzosin hydrochloride extended-release tablets are not indicated for use in the pediatric population. alfuzosin hydrochloride extended-release tabletsare contraindicated for use: - in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [s ee use in specific populations (8.7) and clinical pharmacology (12.3 )]. - with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [ see drug interactions (7.1 ) and clinical pharmacology (12.3 )] . - in patients with known hypersensitivity, such as urticaria and angioedema, to alfuzosin hydrochloride or any component of alfuzosin hydrochloride extended-release tablets [see

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

medihealth (northern) ltd - alfuzosin hydrochloride - oral tablet - 2.5mg

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride extended-release tablets, usp are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. alfuzosin hydrochloride extended-release tablets, usp are not indicated for the treatment of hypertension. alfuzosin hydrochloride extended-release tablets, usp are not indicated for use in pediatric population. alfuzosin hydrochloride extended-release tablets are contraindicated for use: - in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [see use in specific populations(8.7)  and clinical pharmacology (12.3)]. - with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [see drug interactions (7.1) and clinical pharmacology (12.3)] . - in patients with known hypersensitivity, such as urticaria and angioedema, to alfuzosin hydrochloride or any component of alfuzo

Kenya - English - Pharmacy and Poisons Board

alfuzosin hcl bp 10mg - tablet - 10mg tbs - alfuzosin

United States - English - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride extended-release tablets, usp are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. alfuzosin hydrochloride extended-release tablets, usp are not indicated for the treatment of hypertension. alfuzosin hydrochloride extended-release tablets, usp are not indicated for use in pediatric population. alfuzosin hydrochloride extended-release tablets are contraindicated for use: - in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [see use in specific populations(8.7)  and clinical pharmacology (12.3)]. - with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [see drug interactions (7.1)and clinical pharmacology (12.3)] . - in patients with known hypersensitivity, such as urticaria and angioedema, to alfuzosin hydrochloride or any component of al

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited - alfuzosin hydrochloride - tablet prolonged release - 10 milligram